GLONGHUI, May 9 | Merck said Thursday that the treatments it is testing for some patients with endometrial cancer failed late-stage trials. The pharmaceutical company's Keytruda treatment, combined with chemotherapy, is being evaluated in approximately 1,095 post-operative high-risk endometrial cancer patients. The trial did not meet the main goal of disease-free survival, which refers to the time a patient survives without symptoms after initial cancer treatment. The study's other main goal was overall survival, but no formal testing was performed because the trial did not show significant disease-free survival.